Analyst Insights

Canaccord Analyst Upgrades AngioDynamics, Raises PT To $20

Canaccord analyst Jason Mills today upgraded his rating on AngioDynamics Inc. (ANGO) to Buy from Hold, and raised his price target to $20 from $16.

Canaccord Maintains Hold, $74 Price Target on Triumph Group

Canaccord analyst Kenneth Herbert maintains his Hold rating and $74 price target on Triumph Group, Inc. (TGI) following TGI’s announcement that is has settled all outstanding claims associated with …

Canaccord Reiterates Buy Rating For Black Diamond Following The Sale Of Gregory

In a report issued today, Canaccord analyst Camilo Lyon reiterated a Buy rating on shares of Black Diamond, Inc. (BDE) with a $17.

Canaccord Reiterates Buy On Gildan Activewear, Increases PT To $66

In a research note issued today, Canaccord analyst Derek Dley reiterated a Buy rating on Gildan Activewear Inc. (GIL) and raised his price target to $66.

Maxim Keeps ‘Buy’ On Stem Cells Following Interim Phase I/II Trial Data

In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on StemCells Inc. (STEM), and a price target of $2.

Roth Capital Maintains Neutral On Diamondback Energy, Increases PT To $91

In a research note issued today, Roth Capital analyst Joseph Reagor maintained a Neutral rating on Diamondback Energy, Inc. (FANG) and raised his price target to $91.

Roth Capital Maintains Buy On Golden Minerals, Increases Price Target To $1.20

In a research note issued today, Roth Capital analyst Joseph Reagor maintained a Buy rating on Golden Minerals Company (AUMN) and raised his price target to …

Roth Capital Reiterates Buy On Summer Infant, Boosts Price Target To $3.50

Roth Capital recently hosted investor meetings with Summer Infant’s (SUMR) management and came away highly impressed by new CEO Carol Bramson’s strategic vision …

Roth Capital Reiterates Buy On Crown Crafts Following 4QFY14 Earnings

In a research note released this morning, Roth Capital analyst Dave King reiterated coverage with a “Buy” rating on Crown Crafts, Inc. (CRWS), and a price target of $9.

H.C. Wainwright Reiterates Buy On OncoSec Following YTD Results

In a research note issued this morning, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts